MiRNAs Which Target CD3 Subunits Could Be Potential Biomarkers for Cancers

Fariborz Asghari Alashti*, Zarrin Minuchehr*
Department of Bioinformatics, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran

Abstract

Background: T-cells play an important role in the immune response and are activated in response to the presentation of antigens bound to major histocompatibility complex (MHC) molecules participating with the T-cell receptor (TCR). T-cell receptor complexes also contain four CD3 (cluster of differentiation 3) subunits. The TCR-CD3 complex is vital for T-cell development and plays an important role in intervening cell recognition events. Since microRNAs (miRNAs) are highly stable in blood serum, some of which may target CD3 molecules, they could serve as good biomarkers for early cancer detection. The aim of this study was to see whether there is a relationship between cancers and the amount of miRNAs -targeted CD3 molecules.

Methods: Bioinformatics tools were used in order to predict the miRNA targets for these genes. Subsequently, these highly conserved miRNAs were evaluated to see if they are implicated in various kinds of cancers. Consequently, human disease databases were used. According to the latest research, this study attempted to investigate the possible down- or upregulation of miRNAs cancer patients.

Results: We identified miRNAs which target genes producing CD3 subunit molecules. The most conserved miRNAs were identified for the CD3G gene, while CD247 and CD3EAP genes had the least number and there were no conserved miRNA associated with the CD3D gene. Some of these miRNAs were found to be responsible for different cancers, following a certain pattern.

Conclusions: It is highly likely that miRNAs affect the CD3 molecules, impairing the immune system, recognizing and destroying cancer tumor; hence, they can be used as suitable biomarkers in distinguishing cancer in the very early stages of its development.

Introduction

More than 30% of the human genome is controlled by miRNAs, regulating important biological processes [1]. These short non-coding RNAs (21–23 nucleotides long) are considered to be associated with most cancers [2], and have thus attracted the attention of many researchers. miRNAs are bound to the three prime untranslated regions (3’UTR) of target messenger RNAs (mRNAs) before they can be translated to special proteins by making genes off and on [3,4]. They have key roles in lots of cellular processes such as cell proliferation [4], cell division [5], apoptosis [6], differentiation, self-renewal [7], stress response and cancer [5]. Down-regulation of some miRNAs (for example miR-34) which is the result of reduced expression, leads to an increase in cells in certain types of cancers [8]. The expression of the majority of miRNAs is reduced in human cancers [9,10,11], which is in contrast to the overexpression certain miRNAs leading to the progression of tumorigenesis [11]. Therefore, miRNAs can act as both tumor suppressors or oncogenes, and their expression may provide a predictive diagnostic value [11]. miRNAs also play an important role in the development of the immune system in which their proper expression can lead to advanced growth, that may otherwise, lead to an interruption of immunity [12].

There is strong evidence that has verified the effectiveness of miRNAs in the immune system. Accordingly, miRNAs can affect the development of B cells [13] and T cells. They can also increase monocyte and neutrophil levels, and are responsible for antibody switching and the release of inflammatory mediators, which are released by the immune cells during times when harmful agents invade the body [14]. miRNAs are stable and consistent in individuals of the same species and can be used as potential biomarkers for the recognition of various cancers and other diseases [15,16]. miRNA signatures in the blood are similar in men and women in different ages [17]. Some findings suggest that they can be accepted as suitable biomarkers, for instance, miR-29a and miR-92 plasma levels were found to be different in controls and colorectal cancers [18]. In fact, an increase in the levels of miR-21, miR-92 and miR-93 could be regarded as a clinical biomarker of ovarian cancer [19].
Methods

Ensembl genome database release 70 updated - January 2013, [33]. In order to recognize the genes producing these subunits, the important role in T cell receptor function and T cell development Delta, CD3-Epsilon and CD3-Zeta that bind to the TCR, leading biomarkers in the detection of cancers.

CD3 proteins which could be ultimately used as reasonable antigens, this study attempted to focus on the miRNAs that target the importance of the role of CD3 molecules in recognition of help in finding the best miRNA target gene.

There are some microRNA target gene databases such as StarBase [31], miRwalk [32], targetScan [32] etc. which massage [30]. There are some microRNA target gene databases [34]. In this database the name and ID of genes, which coded for molecules in humans, were derived. Using the TargetScan Human database release 6.2 (http://www.targetscan.org/ (updated -june 2012)) [35], and choosing broadly conserved, conserved and poorly conserved microRNA family options, we (http://asia.ensembl.org/Homo_sapiens/Info/Index/) was used [34]. In this database the name and ID of genes, which coded for molecules in humans, were derived. Using the TargetScan Human database release 6.2 (http://www.targetscan.org/ (updated -june 2012)) [35], and choosing broadly conserved, conserved and poorly conserved microRNA family options, we obtained miRNAs that were able to target these genes. It is worth mentioning that this study only considered the results of conserved microRNA families, but no other genes.

Table 1. The name and other characteristics of genes which are expressed to produce CD3 subunit molecules.

| Protein Name | Gene symbol | Gene ID | Location |
|--------------|-------------|---------|----------|
| CD3G molecule, gamma | CD3G | ENSG00000160654 | 11:118215059–118258761 |
| CD3D molecule, delta | CD3D | ENSG00000167286 | 11:118209669–118213459:–1 |
| CD3E molecule, epsilon associated protein | CD3EAP | ENSG00000117877 | 19:45909467–45914024:1 |
| CD3 molecule, zeta | CD247 | ENSG00000198821 | 1:167399877–167487847:–1 |

doi:10.1371/journal.pone.0078790.t001

Table 2. miRNAs which were predicted to target CD3G (broadly conserved).

| Predicted miRNAs | Target region of gene pairing with miRNA |
|------------------|----------------------------------------|
| Has-miR-1200     | Position 2-8 of CD3G 3’ UTR              |
| Has-miR-378d     | Position 17-23 of CD3G 3’ UTR            |
| Has-miR-378e     | Position 17-23 of CD3G 3’ UTR            |
| Has-miR-378i     | Position 17-23 of CD3G 3’ UTR            |
| Has-miR-378c     | Position 17-23 of CD3G 3’ UTR            |
| Has-miR-422a     | Position 17-23 of CD3G 3’ UTR            |
| Has-miR-378h     | Position 17-23 of CD3G 3’ UTR            |
| Has-miR-378b     | Position 17-23 of CD3G 3’ UTR            |
| Has-miR-378f     | Position 17-23 of CD3G 3’ UTR            |
| Has-miR-3690     | Position 18-24 of CD3G 3’ UTR            |
| Has-miR-619      | Position 19-25 of CD3G 3’ UTR            |
| Has-miR-4446-3p  | Position 94-101 of CD3G 3’ UTR           |
| Has-miR-2909     | Position 96-103 of CD3G 3’ UTR           |
| Has-miR-4777-5p  | Position 103-109 of CD3G 3’ UTR          |
| Has-miR-136      | Position 132-139 of CD3G 3’ UTR          |
| Has-miR-515-5p   | Position 134-140 of CD3G 3’ UTR          |
| Has-miR-4659a-3p | Position 137-144 of CD3G 3’ UTR          |
| Has-miR-4659b-3p | Position 137-144 of CD3G 3’ UTR          |
| Has-miR-494      | Position 203-209 of CD3G 3’ UTR          |
| Has-miR-593      | Position 405-412 of CD3G 3’ UTR          |

doi:10.1371/journal.pone.0078790.t002

Table 3. miRNAs which were predicted to target CD3EAP (broadly conserved).

| Predicted miRNAs | Target region of gene pairing with miRNA |
|------------------|----------------------------------------|
| Has-miR-138      | Position 95–101 of CD3EAP 3’ UTR        |

doi:10.1371/journal.pone.0078790.t003
Table 4. miRNAs which were predicted to target CD247 (broadly conserved).

| Predicted miRNAs | Target region of gene pairing with miRNA |
|------------------|----------------------------------------|
| Has-miR-761      | Position 410–416 of CD247 3’ UTR      |
| Has-miR-214      | Position 410–416 of CD247 3’ UTR      |
| Has-miR-3619-5p  | Position 410–416 of CD247 3’ UTR      |

Subsequently, every miRNA of the conserved microRNA family has been investigated separately. In order to find out in which type of cancer, these miRNAs play an important role, we used the Human miRNA & Disease Database (HMDD) [35]. In this database, diseases related to miRNAs and their role were identified. A search for miRNAs was also performed by browsing the miRCancer Database [37]. In this database, miRNAs were searched according to their name, eventually leading to identification of cancers they were responsible for. This database also showed whether miRNAs are upregulated or downregulated.

**Results**

The TCR-CD3 complex is a multimeric structure present on the T-cells surface. Human CD3 consists of four subunits: CD3-Gamma, CD3-Delta, CD3-Epsilon and CD3-zeta. To know the name and features of genes which are involved in expressing CD3 subunit molecules, the Ensembl database was used, and one gene for each subunit was found and identified as; CD3G, CD3D, CD3EAP and CD247, respectively (Table 1).

For each of the four genes involved in producing CD3 subunits, the TargetScanHuman database (release 6.2, June 2012) was used [35] to identify and predict miRNAs which could target these genes. In this study, only highly conserved miRNA families have been considered and poorly conserved miRNA families have been omitted. For the CD3G gene, 21 miRNAs were predicted that target this gene (Table 2). One miRNA was predicted for the CD3EAP gene (responsible for producing the CD3E molecule, epsilon) (Table 3), three miRNAs for the CD247 gene (responsible for producing the CD3 molecule, delta) in both transcripts of NM_000734 (1041 nt) and NM_198053 (1041 nt) (Table 4). miRNA were not predicted for the CD3D gene (responsible for producing the CD3 molecule, delta) in both transcripts of NM_000732 (88 nt) and NM_001040651 (88 nt).

Each of the predicted miRNAs were then reviewed in related research papers to see if these miRNAs were down-regulated or up-regulated in tumor tissues and the blood serum of cancer patients.

The results showed that has-miR-378, which was a miRNA predicted for CD3G, had increased in all blood sera belonging to patients suffering from castration resistant prostate cancer (CRPC) [38], renal cell carcinoma (RCC) [16],39 and gastric cancer (GC) [40]; besides, cancer tissues in patients with bladder cancer (BC) [41], carcinoma basal cells [42], colorectal cancer (CRC) [43], oral carcinoma [44], laryngeal carcinoma [45] and gastric cancer [46]. This was in contrast to reduced miRNA level in adjacent non-tumoral tissues. Has-miR-422a, has-miR-593 and has-miR-494 which represented other miRNAs predicted for CD3G also showed a similar decrease in levels in tumor tissues. For instance, reduction in levels were observed for miR-422a in patients with laryngeal carcinoma [45] and colorectal cancer [43], miR-593 in esophagel cancer patients [47] and miR-494 in cholangiocarcinoma (CCA) [48], lung cancer [49] and gastrointestinal tumor [50]. The above observations were in agreement with the data of this study. Except for miR-515 and miR-136, which were only cited once (oral squamous cell [44] and lung cancer [51] respectively), which showed an increasing number of miRNAs in tumor tissues, no other literature is available regarding the number of other miRNAs predicted for targeting CD3G in tumor tissues or blood sera of cancer patients (Table 5).

The only miRNA predicted for targeting the CD3EAP gene, involved in CD3E expression, was hsa-miR-138. Studies showed that levels of this miRNA had decreased in tumour tissues of patients suffering from colorectal cancer [52], hepatocellular carcinoma (HCC) [53], tongue squamous cell carcinoma (TSCC) [54], papillary thyroid carcinoma [55], head and neck squamous cell carcinoma (HNSCC) [56] and squamous cell carcinoma (SCC) [57] (Table 6).

Studies on the predicted miRNAs targeting CD247, which were involved in the expression of the CD3-zeta molecule, showed that there were three miRNAs which targeted the gene. Except for has-miR-214, no reports have been cited so far regarding the levels of

Table 5. The status of miRNAs from the first group which affect the CD3G gene responsible for the CD3-gamma subunit in cancer tissues relative to adjacent normal tissues.

| miR-ID   | Profile         | Cancer                      | reference |
|----------|-----------------|-----------------------------|-----------|
| Has-miR-378 | down-regulated | bladder cancer          | [41]      |
|          |                 | carcinoma basal cells      | [42]      |
|          | down-regulated | CRC tumor               | [43]      |
|          | down-regulated | oral carcinoma           | [44]      |
|          | down-regulated | laryngeal cancer         | [45]      |
|          | down-regulated | stomach neoplasm         | [46]      |
| Has-miR-422a | down-regulated | laryngeal neoplasm       | [45]      |
|          | down-regulated | colorectal neoplasm       | [43]      |
| Has-miR-593 | down-regulated | esophageal cancer (EC)   | [47]      |
| Has-miR-494 | down-regulated | cholangio carcinoma (CCA) | [48]      |
|          | down-regulated | lung cancer              | [49]      |
|          | down-regulated | gastrointestinal neoplasm | [50]      |
| Has-miR-515 | up-regulated   | oral squamous cell carcinoma | [44]     |
| Has-miR-136 | up-regulated   | lung neoplasm            | [51]      |

doi:10.1371/journal.pone.0078790.t005

Table 6. The status of miRNA from the second group which affect the CD3EAP gene responsible for the CD3-epsilon subunit in cancer tissues relative to adjacent normal tissues.

| miR-ID   | Profile         | Cancer                      | reference |
|----------|-----------------|-----------------------------|-----------|
| Has-miR-138 | down-regulated | colorectal cancer          | [52]      |
|          | down-regulated | HCC                        | [53]      |
|          | down-regulated | TSCC                       | [54]      |
|          | down-regulated | papillary thyroid carcinoma | [55]      |
|          | down-regulated | HNSCC                      | [56]      |
|          | down-regulated | SCC                        | [57]      |

doi:10.1371/journal.pone.0078790.t006
miR-761 and miR-3619-5p in tumor tissues. Most of the data obtained in this study showed that miR-214 levels decreased in tumor tissues when compared to its relative normal tissue (Table 7). miR-214 levels had decreased in tumor tissues of patients suffering from esophageal squamous cell carcinoma (ESCC) [58], breast cancer [59], cervical cancer [60], hepatocellular carcinoma (HCC) [61] [62], squamous cell carcinoma (SCC) [63], cholangiocarcinoma metastasis [64] and primary central nervous system cancer [65]. In contrast, gastric cancer [66], ovarian cancer [67] and pancreatic cancer [68] are examples of cancers in which miR-214 levels increased (Table 7). With regard to the miR-214 copy number in blood serum studies, an increase in miRNA levels was observed in the blood sera of patients with prostate [69] and breast [70] cancers (Table 8).

### Discussion

miRNAs can act as tumor oncogenes and suppressors and negatively regulate gene expression [71]. This task can be performed through degradation of mRNA or repression of translation [72]. Many recent studies have described miRNAs as key regulators of the processes in the immune system, which have critical roles in the induction, function and maintenance of the regulatory T-cell lineage [73]. The TCR-CD3 complex, which is a complex transmembrane receptor, plays a decisive role in the immune system [74]. Four invariant chains, physically associated with TCR, include: CD3-gamma, -delta, -epsilon and -zeta [75]. miRNAs have previously been identified as powerful biomarkers in a variety of cancers [16,17,18,76,77,78], and in this study, the bioinformatics analysis predicted miRNAs which targeted genes expressing the CD3 subunits, including CD3-gamma, CD3-delta, CD3-epsilon and CD3-zeta. Our aim was to identify miRNAs which affect subunits of the immune system and to validate them by reviewing the studies which had previously been carried out, so as to evaluate them as potential biomarkers for diagnosis or early detection of cancers. In this study, the TargetScanHuman database identified 13 miRNAs (miR-1200, miR-378d,e,i,c,h,f, miR-422a, miR-3690, miR-619, miR-4446-3p, miR-299d, miR-4777-5p, miR-136, miR-515-5p, miR-4659a,b-3p, miR-494 and miR-593) which were conserved and similar to the CD3G gene. One miRNA (miR-138) was found to be conserved and similar to the CD3EAP gene and three conserved miRNAs (miR-761, miR-214 and miR-3619-5p) were shown to be similar to the CD247 gene. However, no miRNAs were found to be conserved and similar to the CD3D gene [35]. From the first group only 6 miRNAs (miR-378, miR-422a, miR-593 and miR-494, miR-515 and miR-136), from the second group one miRNA (miR-130) and from the third group only one miRNA (miR-214) were identified and studied, based on their levels in tissues or blood sera of different cancer patients. miR-378, miR-422a, miR-593 and miR-494 from the first group, which affected the CD3G gene (responsible for the CD3-gamma subunit), and were down-regulated in cancer tissues, when compared to adjacent normal tissues (Table 5), whereas miR-378 was up-regulated in blood sera of cancer patients (Table 8). With respect to a number of studies, miR-515 and miR-136 were up-regulated in cancer tissues (Table 5). miR-130 (Table 6) from the second group (predicted for targeting the CD3EAP gene responsible for the CD3-epsilon subunit) was down-regulated, and miR-214 from the third group (predicted for targeting the CD247 gene responsible for the CD3-zeta subunit), was down-regulated in cancer tissues investigated in most of the studies. However, these were reported to be up-regulated in only a few research papers (Table 7). miRNAs are currently being considered as down-regulated tumor suppressors and up-regulated oncomiRs [52,79]. Based on the cases that miR-378 and miR-214 were up-regulated in the blood serum of cancer patients (Table 8) and down-regulated in the tumor tissues; therefore, it can be concluded that they can function as upregulated oncomiRs miRNAs on subunits of the TCR-CD3 complex.

### Conclusion

Since miR-378, miR-422a, miR-593, miR-494, miR-130 and miR-214 could target the CD3 subunits, some of which have been studied in different cancers and have been considered as biomarkers to detect cancer at the early stages, it is then highly likely that miRNAs damage the immune system so that it cannot distinguish cancer cells. Hence, their presence in the blood serum as biomarkers for early diagnosis of cancer could help us to understand the disability of immune system. Although this study looks bioinformatically reliable, more laboratory studies are needed to support these findings.

### Acknowledgments

We thank Dr. Parvin Shariati, for her valuable scientific comments on our work.
Author Contributions
Conceived and designed the experiments: FAA. ZM. Performed the experiments: FAA ZM. Analyzed the data: FAA ZM. Wrote the paper: FAA ZM.

References

1. Bano R, Rashid H (2011) Computational analysis of human miRNAs phylogenetics. African Journal of Biotechnology 10(18): 3633–3643.
2. He L, Thomson JM, Herrmann MT, Hernandez-Monge E, Ma D, et al. (2005) A microRNA polymerase as a potential human oncogene. Nature 435: 820–823.
3. He L, Hannah GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522–531.
4. O’Donnell KA, Wenzel EA, Zeller KI, Dang CV, Mandell JT (2005) c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435: 839–843.
5. Croce CM, Calin GA (2005) miRNAs, cancer, and stem cell division. Cell 122: 6–7.
6. Kren BT, Wong PY, Sarver A, Zhang X, Zeng Y, et al. (2009) MicroRNAs identified in highly purified liver-derived mitochondria may play a role in apoptosis. RNA Biol 6: 65–72.
7. Esquela-Kerscher A, Slack FJ (2006) Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259–269.
8. He X, He L, Hannah GJ (2007) The guardian’s little helper: microRNAs in the p53 tumor suppressor network. Cancer Res 67: 11099–11101.
9. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435: 834–838.
10. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, et al. (2007) MicroRNA signatures in human ovarian cancer. Cancer Res 67: 8099–8107.
11. Iorio MV, Ferracin M, Liu CG, Vassone A, Spizzo R, et al. (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065–7070.
12. Xiao C, Rajesky K (2009) MicroRNA control in the immune system: basic principles. Cell 136: 26–36.
13. Zimmerman AL, Wu S (2011) MicroRNAs, cancer and cancer stem cells. Cancer Lett 300: 10–19.
14. Lindsay MA (2008) microRNAs and the immune response. Trends Immunol 29: 83–91.
15. Chen X, Ba Y, Ma L, Cai X, Yin Y, et al. (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997–1006.
16. Redova M, Poprach A, Nekvindova J, Iliev R, Radova L, et al. (2012) Circulating miR-370 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med 10: 55.
17. Taylor DD, Gercel-Taylor C (2008) MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110: 13–23.
18. Huang Z, Huang D, Ni S, Peng Z, Sheng W, et al. (2010) Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 127: 118–126.
19. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, et al. (2009) The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 112: 55–59.
20. Miller JP (2002) The discovery of thymus function and of thymus-derived lymphocytes. Immunol Rev 185: 7–14.
21. Sutherland JS, Goldberg GL, Hammet MV, Uldrich AP, Berzins SP, et al. (2009) MicroRNA expression profiling identifies microRNAs highly deregulated in colorectal cancer. J Cell Mol Med 16: 2655–2666.
22. Scapoli L, Palmieri A, Lo Muzio L, Pessotti F, Rubini C, et al. (2010) MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopath Pharmacol 23: 1229–1234.
23. Wang P, Tu W, Wang X, Zhu W (2010) [Primary, study of miRNA expression patterns in laryngeal carcinoma by microarray]. Chin J Cancer Res 22: 380–387.
24. Wang P, Tu W, Wang X, Zhu W (2010) [Primary, study of miRNA expression patterns in laryngeal carcinoma by microarray]. J Cancer Res Clin Oncol 136: 336–343.
25. Wang P, Tu W, Wang X, Zhu W (2010) [Primary, study of miRNA expression patterns in laryngeal carcinoma by microarray]. J Cancer Res Clin Oncol 136: 336–343.
26. Skrygan M, Sand D, Georgas D, Hahn SA, et al. (2012) Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med 16: 2655–2666.
27. Scapoli L, Palmieri A, Lo Muzio L, Pessotti F, Rubini C, et al. (2010) MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopath Pharmacol 23: 1229–1234.
28. Wang P, Tu W, Wang X, Zhu W (2010) [Primary, study of miRNA expression patterns in laryngeal carcinoma by microarray]. Chin J Cancer Res 22: 380–387.
29. Wang P, Tu W, Wang X, Zhu W (2010) [Primary, study of miRNA expression patterns in laryngeal carcinoma by microarray]. J Cancer Res Clin Oncol 136: 336–343.
56. Liu X, Wang C, Chen Z, Jin Y, Wang Y, et al. (2011) MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. Biochem J 440: 23–31.
57. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, et al. (2008) Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue. Clin Cancer Res 14: 2588–2592.
58. Huang SD, Yuan Y, Zhang CW, Li BL, Gong DJ, et al. (2012) MicroRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma. Mol Cancer 11: 51.
59. Derfoul A, Juan AH, Filippantionio MJ, Palanisamy N, Ried T, et al. (2011) Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. Carcinogenesis 32: 1607–1614.
60. Peng RQ, Wan HY, Li HF, Liu M, Li X, et al. (2012) MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7. J Biol Chem 287: 14301–14309.
61. Shih TC, Tien YJ, Wen CJ, Yeh TS, Yu MC, et al. (2012) MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma. J Hepatol 57: 584–591.
62. Duan Q, Wang X, Gong W, Ni L, Chen C, et al. (2012) ER stress negatively modulates the expression of the miR-199a/214 cluster to regulates tumor survival and progression in human hepatocellular cancer. PLoS One 7: e31510.
63. Yamane K, Jinmin M, Eroh T, Kobayashi Y, Shitouzono N, et al. (2013) Down-regulation of miR-124/~214 in cutaneous squamous cell carcinoma mediates abnormal cell proliferation via the induction of ERK. J Mol Med (Berl) 91: 69–81.
64. Li B, Han Q, Zhu Y, Yu Y, Wang J, et al. (2012) Down-regulation of miR-214 contributes to intrahepatic cholangiocarcinoma metastasis by targeting Twist. FEBS J 279: 2393–2398.
65. Fischer L, Hummel M, Korfel A, Lenz D, Joehrens K, et al. (2011) Differential microRNA expression in primary CNS and nodal diffuse large B-cell lymphomas. Neuro Oncol 13: 1090–1098.
66. Li X, Zhang Y, Zhang H, Liu X, Gong T, et al. (2011) miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res 9: 824–833.
67. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, et al. (2008) MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68: 425–433.
68. Zhang NJ, Ye H, Zeng CW, He B, Zhang H, et al. (2010) Dysregulation of miR-15a and miR-214 in human pancreatic cancer. J Hematol Oncol 3: 46.
69. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, et al. (2009) Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 4: e6229.
70. Schwarzenbach H, Milde-Langosch K, Steinbach B, Muller V, Pantel K (2012) Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Res Treat 134: 933–941.
71. Winter J, Jung S, Keller S, Gregory RI, Diederichs S (2009) Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 11: 220–234.
72. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281–297.
73. Schwertheim S, Shen SY, Worn K, GrabeD’S, Schmidt KW (2009) Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma. Horm Metab Res 41: 475–481.
74. Call ME, Pyrdol J, Wicherppenig KW (2004) Stoichiometry of the T-cell receptor-CD3 complex and key intermediates assembled in the endoplasmic reticulum. EMBO J 23: 2540–2557.
75. Clevres H, Aracon B, Wilman T, Terhorst C (1988) The T cell receptor/CD3 complex: a dynamic protein ensemble. Annu Rev Immunol 6: 629–662.
76. Sarma NJ, Tijrvedhi V, Subramanian V, Shenoy S, Crippin JS, et al. (2012) Hepatitis C virus mediated changes in miRNA-449a modulates inflammatory biomarker YKL40 through components of the NOTCH signaling pathway. PLoS One 7: e50826.
77. Reid G, Kirschner MB, van Zandwijk N (2011) Circulating microRNAs: Association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 80: 193–200.
78. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, et al. (2010) A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One 5: e13735.
79. Visone R, Croce CM (2009) MiRNAs and cancer. Am J Pathol 174: 1131–1138.